William Blair Issues Pessimistic Outlook for Biogen Earnings

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at William Blair lowered their Q2 2025 earnings estimates for Biogen in a report issued on Tuesday, May 27th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings per share of $4.09 for the quarter, down from their prior forecast of $4.34. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen’s FY2025 earnings at $14.68 EPS.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing analysts’ consensus estimates of $3.26 by ($0.24). Biogen had a net margin of 16.87% and a return on equity of 14.98%. The firm had revenue of $2.43 billion for the quarter, compared to the consensus estimate of $2.25 billion. During the same period in the previous year, the business earned $3.67 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis.

BIIB has been the topic of a number of other reports. Citigroup dropped their price target on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Morgan Stanley dropped their price target on shares of Biogen from $157.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. Bank Of America (Bofa) lowered their price objective on shares of Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 11th. Sanford C. Bernstein began coverage on shares of Biogen in a research report on Tuesday, February 11th. They issued a “market perform” rating and a $160.00 price objective on the stock. Finally, Scotiabank lowered their price objective on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating on the stock in a research report on Thursday, February 13th. Twenty investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $191.30.

Biogen Stock Down 1.2%

BIIB opened at $131.11 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The company’s 50-day moving average is $123.43 and its 200 day moving average is $139.25. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The firm has a market capitalization of $19.21 billion, a P/E ratio of 11.72, a PEG ratio of 1.51 and a beta of 0.12.

Insider Activity at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. The trade was a 43.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Biogen

Several hedge funds have recently bought and sold shares of the company. Signaturefd LLC grew its stake in Biogen by 3.5% during the fourth quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 71 shares in the last quarter. Quent Capital LLC grew its stake in Biogen by 31.9% in the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock worth $46,000 after buying an additional 72 shares in the last quarter. Principal Securities Inc. grew its stake in Biogen by 30.1% in the 4th quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company’s stock worth $52,000 after buying an additional 78 shares in the last quarter. Israel Discount Bank of New York grew its stake in Biogen by 6.2% in the 4th quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company’s stock worth $215,000 after buying an additional 82 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators grew its stake in Biogen by 5.7% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,612 shares of the biotechnology company’s stock worth $247,000 after buying an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.